Biomed Res Int. 2013;2013:460546. doi: 10.1155/2013/460546. Epub 2013 Oct 29.
Prostate cancer (Pca) is a heterogeneous disease; its etiology appears to be related to genetic and epigenetic factors. Radiotherapy and hormone manipulation are effective treatments, but many tumors will progress despite these treatments. Molecular imaging provides novel opportunities for image-guided optimization and management of these treatment modalities. Here we reviewed the advances in targeted imaging of key biomarkers of androgen receptor signaling pathways. A computerized search was performed to identify all relevant studies in Medline up to 2013. There are well-known limitations and inaccuracies of current imaging approaches for monitoring biological changes governing tumor progression. The close integration of molecular biology and clinical imaging could ease the development of new molecular imaging agents providing novel tools to monitor a number of biological events that, until a few years ago, were studied by conventional molecular assays. Advances in translational research may represent the next step in improving the oncological outcome of men with Pca who remain at high risk for systemic failure. This aim may be obtained by combining the anatomical properties of conventional imaging modalities with biological information to better predict tumor response to conventional treatments.
前列腺癌（Pca）是一种异质性疾病；其病因似乎与遗传和表观遗传因素有关。放射治疗和激素治疗是有效的治疗方法，但许多肿瘤尽管接受了这些治疗仍会进展。分子成像为这些治疗方法的图像引导优化和管理提供了新的机会。在这里，我们回顾了雄激素受体信号通路关键生物标志物靶向成像的进展。在 Medline 中进行了计算机检索，以确定截至 2013 年的所有相关研究。目前用于监测控制肿瘤进展的生物学变化的成像方法存在众所周知的局限性和不准确性。分子生物学和临床成像的紧密结合可以简化新的分子成像剂的开发，为监测许多生物学事件提供新的工具，这些事件在几年前还是通过传统的分子检测来研究的。转化研究的进展可能代表着提高前列腺癌高危全身转移风险男性的肿瘤学结果的下一步，这一目标可以通过将传统成像方式的解剖学特性与生物学信息相结合来实现，以更好地预测肿瘤对传统治疗的反应。
